[Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3].
To evaluate the efficacy and safety of 1-alpha(OH) vitamin D3 in the treatment of postmenopausal osteoporosis, we conducted a six month prospective, double blind study in 20 postmenopausal women. Women were randomly divided into two groups. One group (n=12) received 1-alpha(OH) vitamin D3 (0.25 mcg twice a day), the other (n=8) received placebo. At the same time both groups received one calcium tablet (500 mg daily). In the group treated with 1-alpha(OH) vitamin D3, there was a significant increase in serum calcium (p<0.01), urinary excretion of calcium (p<0.05), and serum 1.25(OH)2 vitamin D3 concentracion (p<0.01), while parathyroid hormone levels showed tendency to fall without statistical significance. In the group treated with placebo and calcium, after treatment there was only a significant increase in serum calcium (p<0.01). In the placebo group occurrance of one new vertebral fracture was recorded. There were no side effects during treatment in both groups. It was concluded that the administration of 1-alpha(OH) vitamin D3 is a safe and potentially efficient drug in the treatment of postmenopausal osteoporosis.
Petkakov
M
M
Popović
V
V
Milić
D
D
Damjanović
S
S
Manojlović
D
D
Mićić
J
J
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000008:administration & dosage / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000097:blood / Q000627:therapeutic use*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood
D050071:Bone Density Conservation Agents; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D002118:Calcium; C008088:alfacalcidol